Home | Welcome to Contract Pharma   
Last Updated Friday, May 29 2015

Print RSS Feed

Search Results for 'Financial Report: Merck'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Published April 28, 2015
Foreign exchange and Consumer Care divestiture impact results Read More »
Published February 4, 2015
Patent expiries and divestitures impact results Read More »
Published October 28, 2014
Merck 3Q Revenues: $10.6 billion  (-4%) 3Q Earnings: $842 million (-27%) YTD Revenues: $31.8 billion (-3%) YTD Earnings: $4.6 billion (+24%) Comments: Pharmaceutical sales were $9.1 billion in the quarter, down 4%. JANUVIA/JANUMET sales wer… Read More »
Published April 29, 2014
Revenues down 4% in the quarter Read More »
Published October 28, 2013
Revenues down 4% in the quarter Read More »
Published May 1, 2013
Singulair expiry continues to impact results Read More »
Published February 1, 2013
Revenues down 5% in the quarter Read More »
Published October 26, 2012
Key products help offset August Singulair patent expiry Read More »
Published July 27, 2012
Pharma sales up 2%, hurt by Remicade settlement Read More »
Published April 27, 2012
Pharmaceuticals sales up 3% Read More »
Published February 2, 2012
Januvia, Janumet, Isentress, and Gardasil see double-digit growth Read More »
Published October 31, 2011
Revenues up 8% Read More »
Published July 30, 2010
Singulair sales in the quarter were flat at $1.3 billion. Remicade sales were $669 million (+18%). Read More »
Published May 4, 2010
Singulair sales were $1.2 billion (+10%). Remicade sales were $674 million (+30%). Read More »
Published February 16, 2010
Worldwide sales of Singulair were $1.3 billion in the quarter (+12%), and for the year sales were $4.7 billion (+7%). Read More »
Published October 22, 2009
Singulair sales were $1.1 billion in the quarter (+5%). Read More »
Published July 21, 2009
Worldwide sales of Singulair were $1.3 billion in the quarter (+ 16%). Combined sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, were $1.0 billion (-10%). Read More »
Published April 21, 2009
Worldwide sales of Singulair were $1.1 billion (-4%). Combined global sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, were $945 million (-23%). Read More »
Published October 22, 2008
Merck 3Q Revenues: $5.9 billion (-2%) 3Q Earnings: $1.1 billion (-28%) YTD Revenues: $17.8 billion (-1%) YTD Earnings: $6.2 billion (+26%) Comments: Januvia sales were $379 million in the quarter (+105%). Sales of Isentress were $107 m… Read More »
Published July 22, 2008
Merck 2Q Revenues: $6.1 billion (-1%) 2Q Earnings: $1.8 billion (+5%) YTD Revenues: $11.9 billion (flat) YTD Earnings: $5.1 billion (+50%) Comments: Worldwide sales of Singulair were $1.1 billion in the quarter (-1%). Combined worldwid… Read More »
Published April 21, 2008
Merck 1Q Revenues: $5.8 billion (+1%) 1Q Earnings: $3.3 billion (+94%) Comments: Worldwide sales of Singulair were $1.1 billion (+10%); Cozaar and Hyzaar sales were $847 million (+6%); Fosamax and Fosamax Plus D sales were $470 million (-37… Read More »
Published January 30, 2008
Merck 4Q07 4Q Revenues: $6.2 billion (+3%) 4Q Loss: $1.6 billion (earnings were $473.9 million in 4Q06) FY Revenues: $24.2 billion (+7%) FY Earnings: $3.3 billion (-26%) Comments: 4Q Singulair sales were up 20% to $1.2 billion and FY s… Read More »
Published January 30, 2007
Merck 4Q Revenues: $6 billion (+5%) 4Q Earnings: $473.9 million* (earnings were $1.1 billion 4Q2005) FY Revenues: $22.6 billion (+3%) FY Earnings: $4.4 billion (-4%) Comments: Singulair sales were $960 million for the quarter, up… Read More »
Published July 24, 2006
Merck 2Q Revenues: $5.8 billion (+6%) 2Q Earnings: $1.5 billion (+108%)* YTD Reveneus: $11.2 billion (+3%) YTD Earnings: $3 billion (+44%) Comments: Zocor sales were $990 million, down 14% due to loss of marketing exclusivity. Sin… Read More »
Published April 20, 2006
Merck 1Q Revenues: $5.4 billion (+1%) 1Q Earnings: $1.5 billion (+11%) Comments: Zocor and Singulair performed well in the quarter. Worldwide sales of Singulair were $801 million, up 9%. Worldwide Zocor sales were $1.1 billion, down 4%,… Read More »


Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On